BACKGROUND: IRX-2 is a primary biologic which has been used for the therapy of head and neck squamous cell cancer (HNSCC) with promising clinical results. Since NK-cell function is compromised in HNSCC patients, we tested the effects of IRX-2 on the restoration of human NK-cell functions in vitro. METHODS: Peripheral blood mononuclear cells (PBMC) were isolated from 23 HNSCC patients and 10 normal controls (NC). The NK-cell phenotype and functions were compared before and after culture ± IRX-2 or ± 50 IU/ml rhIL-2. Flow cytometry was used to study the NK-cell phenotype, cytotoxic activity and cytokine expression. RESULTS: Impaired NK-cell cytotoxicity in HNSCC patients was related to lower expression of NKG2D, NKp30 and NKp46 receptors (P < 0.05) and not to a decreased frequency of NK cells. Incubation of patients' NK cells with IRX-2 up-regulated the percentage of receptor-positive NK cells (P < 0.05). It also up-regulated cytotoxicity of patients' NK cells (P < 0.01) more effectively than rhIL-2 (P < 0.01). IRX-2, but not rhIL-2, protected NK cells from suppression mediated by TGF-β, and it restored (P < 0.05) expression of activating NK-cell receptors and NK-cell cytotoxicity suppressed by TGF-β. Expression of pSMAD was decreased in NK cells treated with IRX-2 but not in those treated with rhIL-2. CONCLUSIONS: IRX-2 was more effective than IL-2 in enhancing NK-cell cytotoxicity and protecting NK-cell function of HNSCC patients in vitro, emphasizing the potential advantage of IRX-2 as a component of future therapies for HNSCC.
BACKGROUND:IRX-2 is a primary biologic which has been used for the therapy of head and neck squamous cell cancer (HNSCC) with promising clinical results. Since NK-cell function is compromised in HNSCCpatients, we tested the effects of IRX-2 on the restoration of human NK-cell functions in vitro. METHODS: Peripheral blood mononuclear cells (PBMC) were isolated from 23 HNSCCpatients and 10 normal controls (NC). The NK-cell phenotype and functions were compared before and after culture ± IRX-2 or ± 50 IU/ml rhIL-2. Flow cytometry was used to study the NK-cell phenotype, cytotoxic activity and cytokine expression. RESULTS: Impaired NK-cell cytotoxicity in HNSCCpatients was related to lower expression of NKG2D, NKp30 and NKp46 receptors (P < 0.05) and not to a decreased frequency of NK cells. Incubation of patients' NK cells with IRX-2 up-regulated the percentage of receptor-positive NK cells (P < 0.05). It also up-regulated cytotoxicity of patients' NK cells (P < 0.01) more effectively than rhIL-2 (P < 0.01). IRX-2, but not rhIL-2, protected NK cells from suppression mediated by TGF-β, and it restored (P < 0.05) expression of activating NK-cell receptors and NK-cell cytotoxicity suppressed by TGF-β. Expression of pSMAD was decreased in NK cells treated with IRX-2 but not in those treated with rhIL-2. CONCLUSIONS:IRX-2 was more effective than IL-2 in enhancing NK-cell cytotoxicity and protecting NK-cell function of HNSCCpatients in vitro, emphasizing the potential advantage of IRX-2 as a component of future therapies for HNSCC.
Authors: Roberta Castriconi; Claudia Cantoni; Mariella Della Chiesa; Massimo Vitale; Emanuela Marcenaro; Romana Conte; Roberto Biassoni; Cristina Bottino; Lorenzo Moretta; Alessandro Moretta Journal: Proc Natl Acad Sci U S A Date: 2003-03-19 Impact factor: 11.205
Authors: J Hadden; E Verastegui; J L Barrera; M Kurman; A Meneses; J W Zinser; J de la Garza; E Hadden Journal: Int Immunopharmacol Date: 2003-08 Impact factor: 4.932
Authors: Jennifer D Wu; Lily M Higgins; Alexander Steinle; David Cosman; Kathy Haugk; Stephen R Plymate Journal: J Clin Invest Date: 2004-08 Impact factor: 14.808
Authors: D S Heo; C Snyderman; S M Gollin; S Pan; E Walker; R Deka; E L Barnes; J T Johnson; R B Herberman; T L Whiteside Journal: Cancer Res Date: 1989-09-15 Impact factor: 12.701
Authors: D Pende; S Parolini; A Pessino; S Sivori; R Augugliaro; L Morelli; E Marcenaro; L Accame; A Malaspina; R Biassoni; C Bottino; L Moretta; A Moretta Journal: J Exp Med Date: 1999-11-15 Impact factor: 14.307
Authors: Gregory N Dietsch; Hailing Lu; Yi Yang; Chihiro Morishima; Laura Q Chow; Mary L Disis; Robert M Hershberg Journal: PLoS One Date: 2016-02-29 Impact factor: 3.240
Authors: Gregory T Wolf; Jeffrey S Moyer; Michael J Kaplan; Jason G Newman; James E Egan; Neil L Berinstein; Theresa L Whiteside Journal: Onco Targets Ther Date: 2018-06-28 Impact factor: 4.147
Authors: Diane M Da Silva; Andrew W Woodham; Paul H Naylor; James E Egan; Neil L Berinstein; W Martin Kast Journal: J Interferon Cytokine Res Date: 2015-12-10 Impact factor: 2.607